JP2022191383A5 - - Google Patents

Download PDF

Info

Publication number
JP2022191383A5
JP2022191383A5 JP2022164041A JP2022164041A JP2022191383A5 JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5 JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
nos
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022164041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022191383A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/022782 external-priority patent/WO2018170351A1/en
Application filed filed Critical
Publication of JP2022191383A publication Critical patent/JP2022191383A/ja
Publication of JP2022191383A5 publication Critical patent/JP2022191383A5/ja
Priority to JP2024055230A priority Critical patent/JP2024088689A/ja
Withdrawn legal-status Critical Current

Links

JP2022164041A 2017-03-16 2022-10-12 抗phf-タウ抗体及びその使用 Withdrawn JP2022191383A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024055230A JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
US62/472,214 2017-03-16
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof
JP2019549574A JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019549574A Division JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024055230A Division JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2022191383A JP2022191383A (ja) 2022-12-27
JP2022191383A5 true JP2022191383A5 (cg-RX-API-DMAC7.html) 2023-06-01

Family

ID=63521020

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549574A Active JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用
JP2022164041A Withdrawn JP2022191383A (ja) 2017-03-16 2022-10-12 抗phf-タウ抗体及びその使用
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019549574A Active JP7159185B2 (ja) 2017-03-16 2018-03-16 抗phf-タウ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗phf-タウ抗体及びその使用

Country Status (22)

Country Link
US (3) US10766953B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596119A4 (cg-RX-API-DMAC7.html)
JP (3) JP7159185B2 (cg-RX-API-DMAC7.html)
KR (2) KR102597462B1 (cg-RX-API-DMAC7.html)
CN (2) CN110799531B (cg-RX-API-DMAC7.html)
AR (1) AR111288A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018234709B2 (cg-RX-API-DMAC7.html)
CA (1) CA3055598A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002566A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992038A1 (cg-RX-API-DMAC7.html)
IL (2) IL268700B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20180021A1 (cg-RX-API-DMAC7.html)
MA (1) MA47789A (cg-RX-API-DMAC7.html)
MX (2) MX2019010922A (cg-RX-API-DMAC7.html)
MY (1) MY205672A (cg-RX-API-DMAC7.html)
PH (1) PH12019501973A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907754RA (cg-RX-API-DMAC7.html)
TW (1) TWI771389B (cg-RX-API-DMAC7.html)
UA (1) UA128385C2 (cg-RX-API-DMAC7.html)
UY (2) UY37635A (cg-RX-API-DMAC7.html)
WO (1) WO2018170351A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202101318B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859665C (en) * 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體
KR102905634B1 (ko) * 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
PE20230385A1 (es) * 2020-04-08 2023-03-06 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos
MX2023000695A (es) * 2020-07-14 2023-04-20 Janssen Pharmaceutica Nv Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica.
JP2023546503A (ja) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ.ベー. 抗タウ抗体の安全な投与方法
CN116829582A (zh) * 2020-10-26 2023-09-29 詹森药业有限公司 安全施用抗Tau抗体的方法
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
CA3203800A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
CA3214310A1 (en) 2021-03-26 2022-09-29 Rupesh Nanjunda Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
ATE335007T1 (de) 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
CA2195672A1 (en) 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4538461B2 (ja) * 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション,インコーポレイテッド ヒトIL−1βアンタゴニスト
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
CA2859665C (en) * 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Similar Documents

Publication Publication Date Title
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2022106952A5 (cg-RX-API-DMAC7.html)
JP2025065427A5 (cg-RX-API-DMAC7.html)
JP2024038003A5 (cg-RX-API-DMAC7.html)
JP2023121798A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2023116770A5 (cg-RX-API-DMAC7.html)
JP2021521843A5 (cg-RX-API-DMAC7.html)
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2023545182A5 (cg-RX-API-DMAC7.html)
JP2022523442A5 (cg-RX-API-DMAC7.html)
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
JP2022534135A5 (cg-RX-API-DMAC7.html)
JP2025016538A5 (cg-RX-API-DMAC7.html)
JP2024531409A5 (cg-RX-API-DMAC7.html)
JP2025067915A5 (cg-RX-API-DMAC7.html)
JP2020537520A5 (cg-RX-API-DMAC7.html)
JP2020511946A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2024546759A5 (cg-RX-API-DMAC7.html)
JP2024546763A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2023510844A5 (cg-RX-API-DMAC7.html)